Why did remdesivir prices surge in 2nd half of Q1?
Remdesivir prices remained stagnant in the 1st half of Q1 due to a decline in the demand till mid-February. The prices surged during the 2nd half of Q1 as demand for Remdesivir from the pharmaceutical sector increased. The Remdesivir market showed positive market sentiments due to the rise in Covid cases.
Is remdesivir available in India?
On 12 May 2020, Gilead announced that it had granted non-exclusive voluntary licenses to five generic drug companies in India and Pakistan to manufacture remdesivir for distribution to 127 countries.
What is the forecast period of remdesivir market research report?
• To estimate and forecast the market size of global remdesivir market from 2021 to 2026 and growth rate until 2026. • To classify and forecast global remdesivir market based on dosage form, route of administration, patient age, application, distribution channel, company, and regional distribution.
How much does remdesivir cost 2020?
On 29 June 2020, Gilead announced that it had set the price of remdesivir at US$390 per vial for the governments of developed countries, including the United States, and US$520 for US private health insurance companies. The expected course of treatment is six vials over five days for a total cost of US$2,340.
Is GILD stock a good buy?
Out of 12 analysts, 2 (16.67%) are recommending GILD as a Strong Buy, 2 (16.67%) are recommending GILD as a Buy, 7 (58.33%) are recommending GILD as a Hold, 0 (0%) are recommending GILD as a Sell, and 1 (8.33%) are recommending GILD as a Strong Sell.
Is Gilead Sciences a publicly traded company?
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know. Gilead Sciences (GILD) closed the most recent trading day at $62.34, moving -0.03% from the previous trading session.
Is Gilead a buy Zacks?
The Zacks database contains over 10,000 stocks. All of those stocks are classified into three groups: Sector, M Industry and X Industry....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Who owns the most Gilead stock?
Top 10 Owners of Gilead Sciences IncStockholderStakeShares ownedThe Vanguard Group, Inc.8.00%100,472,614BlackRock Fund Advisors6.55%82,203,205SSgA Funds Management, Inc.4.62%57,970,959Capital Research & Management Co....4.46%55,951,3796 more rows
Who owns the company Gilead?
Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Gilead Sciences is not owned by hedge funds. Capital Research and Management Company is currently the company's largest shareholder with 16% of shares outstanding.
Is Pfizer a buy Zacks?
How good is it? See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Is Gilead a good company?
Gilead Sciences is a great company to work for. It has great company culture as well as a good work-life balance. Gilead is definitely the leader in infectious diseases. The company is actively expanding its oncology pipeline.
Is Gilead Sciences a buy or sell?
Gilead Sciences has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 4 buy ratings, 9 hold ratings, and 1 sell rating.
What is the EUA for Remdesivir?
How much does Remdesivir cost?
On 1 May 2020, the US Food and Drug Administration granted Gilead emergency use authorization (EUA) for remdesivir to be distributed and used by licensed health care providers to treat adults and children hospitalized with severe COVID‐19. Severe COVID‐19 is defined as patients with an oxygen saturation (SpO2) <= 94% on room air or requiring supplemental oxygen or requiring mechanical ventilation or requiring extracorporeal membrane oxygenation (ECMO), a heart–lung bypass machine. Distribution of remdesivir under the EUA will be controlled by the US government for use consistent with the terms and conditions of the EUA. Gilead will supply remdesivir to authorized distributors, or directly to a US government agency, who will distribute to hospitals and other healthcare facilities as directed by the US government, in collaboration with state and local government authorities, as needed. Gilead stated they were donating 1.5 million vials for emergency use and estimated, as of April 2020, they had enough remdesivir for 140,000 treatment courses and expect to have 500,000 courses by October 2020, and one million courses by the end of 2020.
What is Remdesivir used for?
Being a repurposed drug, the minimum production cost for remdesivir is estimated at US$0.93 per day of treatment.
How many countries are Gilead Sciences contracting with?
Remdesivir was originally created and developed by Gilead Sciences in 2009, to treat hepatitis C and respiratory syncytial virus (RSV). It did not work against hepatitis C or RSV, but was then repurposed and studied as a potential treatment for Ebola virus disease and Marburg virus infections. According to the Czech News Agency, this new line of research was carried out under the direction of scientist Tomáš Cihlář. A collaboration of researchers from the Centers for Disease Control and Prevention (CDC) and Gilead Sciences subsequently discovered that remdesivir had antiviral activity in vitro against multiple filoviruses, pneumoviruses, paramyxoviruses, and coronaviruses.
What is the challenge of remdesivir?
Among the contracting countries were all 27 EU member states plus the United Kingdom, "Albania, Bosnia & Herzegovina, Iceland, Kosovo, Montenegro, North Macedonia, Norway, and Serbia". At the time, the price per treatment course was not disclosed; on 13 October, Reuters reported the price was 2,070 euros, thereby implying the total value of the contract (if all 500,000 courses are ordered) is approximately €1.035 billion. Under the new contract, each participating country will directly place orders with Gilead and pay Gilead directly for its own orders.
When was Remdesivir approved?
Another challenge is getting remdesivir into patients despite the drug's "poor predicted solubility and poor stability." In June 2020, Ligand Pharmaceuticals revealed that Gilead has been managing those issues by mixing Ligand's proprietary excipient Captisol (based on University of Kansas research into cyclodextrin) with remdesivir at a 30:1 ratio. Since that implies an enormous amount of Captisol is needed to stabilize and deliver remdesivir (on top of amounts needed for several other drugs for which the excipient is already in regular use), Ligand announced that it is trying to boost Captisol annual manufacturing capacity to as much as 500 metric tons.
When did the EUA for Remdesivir come into effect?
Remdesivir was approved for medical use in the United States in October 2020. The U.S. Food and Drug Administration (FDA) approved remdesivir based on the agency's analysis of data from three randomized, controlled clinical trials that included participants hospitalized with mild-to-severe COVID‑19. The FDA granted approval and reissued the revised EUA to Gilead Sciences Inc. The FDA approved remdesivir based primarily on evidence from three clinical trials (NCT04280705, NCT04292899, and NCT04292730) of 2043 hospitalized participants with COVID-19. The trials were conducted at 226 sites in 17 countries including the United States.
Referenced Symbols
On 28 August 2020 , the FDA broadened the Emergency Use Authorization (EUA) for remdesivir to include all hospitalized patients with suspected or laboratory-confirmed COVID‑19, irrespective of the severity of their disease. The Fact Sheet was updated to reflect the new guidance.
About the Author
Shares of Gilead Sciences Inc. GILD, +1.16% gained 1.1% in premarket trading on Wednesday after SVB Leerink upgraded the drugmaker to outperform from market perform.
Understanding Hepatitis D: 4 Questions With Professor Maria Buti
Jaimy Lee is a health-care reporter for MarketWatch. She is based in New York.
Charting a Career to Help Reduce Health Inequity: Porscha's Story
Most people are familiar with the hepatitis B (HBV) and hepatitis C (HCV) viruses that attack the liver. But not many have heard of hepatitis D (HDV), the most severe form of viral hepatitis. Peopl...
These 3 Stocks Just Declared Dividend Raises
Dr. Porscha Showers’ route to health sciences wasn’t always a sure thing. Porscha, who grew up in Louisiana, wanted to become an attorney – despite having a mother who worked as a registered nurse ...
Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More
Big names in the food and beverage, industrial, and pharmaceutical sectors are lifting their payouts.
Gilead Sciences Invests in Research for COVID-19 Treatments for All Ages
Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.
3 Biotech Stocks to Buy in February
Children are being hospitalized with COVID 19 at increasingly high rates, and those younger than 5 aren't eligible to receive a vaccine. We’re committed to helping in this area by investing in rese...
Bulls Say
Don't think the slump for biotech stocks that began last year will go on forever. Here's why they chose Gilead Sciences (NASDAQ: GILD), Novavax (NASDAQ: NVAX), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Gilead Sciences): This month is a good time to buy up shares of drugmaker Gilead.
